Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.
about
Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell linesCross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic ImplicationsIdentification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assayCancer biomarker discovery: the entropic hallmark.Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanismsA signature inferred from Drosophila mitotic genes predicts survival of breast cancer patientsIntegrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinomaCombined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cellsTumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.Modulating polo-like kinase 1 as a means for cancer chemopreventionValidating cancer drug targets through chemical geneticsManagement of cutaneous T cell lymphoma: new and emerging targets and treatment options.The role of polo-like kinase 1 in carcinogenesis: cause or consequence?Current assessment of polo-like kinases as anti-tumor drug targets.Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma.Cell Cycle Regulation and Melanoma.Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma.Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.Playing Polo-Like Kinase in NRAS-Mutant Melanoma.Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death.Polo-like kinase 1 (Plk1) in non-melanoma skin cancers.Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis.Depletion of Aurora-A in zebrafish causes growth retardation due to mitotic delay and p53-dependent cell death.SUMOylation regulates the localization and activity of Polo-like kinase 1 during cell cycle in the silkworm, Bombyx mori.RNA interference-mediated knockdown of SIRT1 and/or SIRT2 in melanoma: Identification of downstream targets by large-scale proteomics analysis.ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines.PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia.Antiproliferative in vitro effects of BI 2536-mediated PLK1 inhibition on cervical adenocarcinoma cells.
P2860
Q27334288-81DCB789-D01D-45AA-89A9-091E2AB2AD82Q28076060-64E98AAF-96FD-4F8D-BEEE-D52963EC74C5Q28820936-B8B944D1-771E-464B-83A4-E75D83BCFB7CQ30496149-84219A87-869A-4FCB-A8BE-2CFBD6A717C4Q33761796-0135F739-841E-44C2-87A3-3B01E4339B8AQ33840749-68116B7B-209D-44C6-B5B7-B791595D5D75Q35560770-340ECD8D-77EA-4A12-A6D8-60195E161E41Q36054290-1C92A00D-AF9D-4F7E-AB71-186EF6C0AFFDQ36312159-EC15B56F-80D9-4DB0-817C-24D8C7A347ABQ37398885-481CB7BD-D5EC-4F26-8A62-F6CD568D9D58Q37682665-90983B81-C471-466D-94C0-420871D017F4Q37779884-751E4A32-A1C8-4B86-A785-317607B9E4D6Q37998019-D206B58C-6BA7-41A0-9DE7-C5B334F8FAB3Q38165149-35A852DB-6F34-41CD-9A7E-16DC0AD9F0B2Q38211244-CE8F6A1A-94DF-4EA9-ADD8-C91613396EBAQ38714999-5B2AC3C4-230B-4675-BCC6-3A5B51B267BAQ38735556-298CCEE0-1B01-4E68-B1E5-263B9553977AQ38788138-E14AD3D2-B232-4A3B-AEAA-2AC970A52050Q38795664-E28C5947-468A-436A-B566-3E1EDE4C7845Q38815527-FFC26D49-4067-42BB-BC88-F885214477A6Q38989539-3B2493F0-7B57-4EEA-BF92-FC40D46B4AB2Q39136346-2F0B3C35-9741-47EB-B5A1-090B437321BFQ39146648-61A7D235-7FDC-4D67-A93C-448F0DE23008Q39297998-6097F861-020D-4D63-9910-37A5C5E85111Q39604101-8C58904A-011F-4465-A0EB-A3F053F45D1FQ39633115-4DD2C267-B132-4049-8F2C-BA3183C2C49BQ41875182-C517AA89-ADCD-4A9C-A1CF-668673AA179FQ41927888-7A8B4A5C-917E-468F-A4D8-5E7AC76ACCA2Q42111415-0A2F9060-3B03-4595-BEB9-5489EBD4035DQ42260159-D84652D5-0165-4E4D-9BCC-8D752A4C6CB6Q44733293-118CF7B2-24CB-4B7E-B984-B3187F142416Q47147377-177059CC-5835-4FFB-9B25-67E127B3CC74Q47838931-0130C9F7-1945-4348-B698-4D85D1C58329Q51763031-839DA5F0-E431-49DE-9DBE-56CBCDBA35EFQ53066951-C21D47EE-9129-45BD-AB29-13D23155FA47Q54550277-F0292EBD-6DBA-4578-BBB8-9DBC9E0B6ADF
P2860
Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Targeted depletion of Polo-lik ...... tosis in human melanoma cells.
@ast
Targeted depletion of Polo-lik ...... tosis in human melanoma cells.
@en
Targeted depletion of Polo-like kinase
@nl
type
label
Targeted depletion of Polo-lik ...... tosis in human melanoma cells.
@ast
Targeted depletion of Polo-lik ...... tosis in human melanoma cells.
@en
Targeted depletion of Polo-like kinase
@nl
prefLabel
Targeted depletion of Polo-lik ...... tosis in human melanoma cells.
@ast
Targeted depletion of Polo-lik ...... tosis in human melanoma cells.
@en
Targeted depletion of Polo-like kinase
@nl
P2093
P2860
P356
P1476
Targeted depletion of Polo-lik ...... tosis in human melanoma cells.
@en
P2093
Nihal Ahmad
Travis L Schmit
Vijayasaradhi Setaluri
Vladimir S Spiegelman
Weixiong Zhong
P2860
P2888
P304
P356
10.1038/JID.2009.172
P407
P577
2009-06-25T00:00:00Z
P5875
P6179
1013531105